<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720483</url>
  </required_header>
  <id_info>
    <org_study_id>17-1477</org_study_id>
    <nct_id>NCT03720483</nct_id>
  </id_info>
  <brief_title>Inhaled NAC in Treatment of IPF</brief_title>
  <official_title>Pilot Study to Evaluate Inhaled N-Acetylcysteine in Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine
      (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood,
      and sputum from IPF patients for future research.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine
      (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood,
      and sputum from IPF patients for future research.

      NAC is a medication used to loosen thick mucus. NAC was initially licensed for use in 1968.
      It is on the World Health Organization's List of Essential Medicines, the most effective and
      safe medicines needed in a health system, and it is available as a generic medication and is
      not very expensive. Inhaled NAC has been used as a mucus-dissolving therapy in respiratory
      conditions with excessive and/or thick mucus production.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Pulmonary function - FVC</measure>
    <time_frame>Baseline, week 10, and week 18</time_frame>
    <description>Measure changes in percent predicted FVC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Pulmonary function - DLCO</measure>
    <time_frame>Baseline, week 10, and week 18</time_frame>
    <description>Measure changes in percent predicted DLCO</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis (IPF)</condition>
  <arm_group>
    <arm_group_label>N-acetyl cysteine then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive NAC followed by placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then N-acetyl cysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive placebo followed by NAC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine then Placebo</intervention_name>
    <description>Subject will receive N-acetyl cysteine first followed by Placebo</description>
    <arm_group_label>N-acetyl cysteine then placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo then N-acetyl cysteine</intervention_name>
    <description>Subject will receive Placebo first followed by N-acetyl cysteine</description>
    <arm_group_label>Placebo then N-acetyl cysteine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed by study team with expertise in IPF utilizing standard ATS/ERS definition of
             &quot;probable&quot; or &quot;definite&quot; IPF

          -  DLCO &gt;50% predicted

          -  FVC &gt;60% predicted

          -  FEV1/FVC &gt; 0.7

        Exclusion Criteria:

          -  History of bronchospasm (requiring treatment)

          -  Current acute exacerbation of their IPF disease

          -  Current smoker

          -  Supplemental O2 requirement &gt; 4 liters/min via nasal cannula

          -  History of asthma, COPD, coronary artery disease, or cancer

          -  Currently using NAC, hypertonic saline, or DNase (dornase alfa) inhalation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Steele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Powers Becker</last_name>
    <phone>303-724-6539</phone>
    <email>julie.powers@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

